ID | 65294 |
フルテキストURL | |
著者 |
Nishimura, Tomoka
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ninomiya, Kiichiro
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kaken ID
Nakashima, Mitsutaka
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Akagi, Satoshi
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
Kuribayashi, Tadahiro
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Higo, Hisao
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Hotta, Katsuyuki
Center for Innovative Clinical Medicine, Okayama University Hospital
Kaken ID
publons
researchmap
Maeda, Yoshinobu
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
Ito, Hiroshi
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
Kiura, Katsuyuki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
|
抄録 | A 59-year-old man with a high level of antinuclear antibody received nivolumab and ipilimumab plus che-motherapy for lung cancer. Two weeks after the second course, he was admitted with a fever and severe fa-tigue. Laboratory studies showed elevated markers of myocardial damage, and a myocardial biopsy showed inflammatory cell infiltration, damaged myocardial fibers. Myocarditis was diagnosed as an immune-related adverse event (irAE), and high-dose corticosteroids were initiated. However, his cardiac function rapidly worsened, and he died on the fifth day after admission. There is no established treatment strategy for fulmi-nant myocarditis as an irAE, and the further exploration of viable treatment strategies is required.
|
キーワード | myocarditis
nivolumab plus ipilimumab
irAE
case report
|
発行日 | 2023-05-01
|
出版物タイトル |
Internal Medicine
|
巻 | 62巻
|
号 | 9号
|
出版者 | The Japanese Society of Internal Medicine
|
開始ページ | 1319
|
終了ページ | 1322
|
ISSN | 0918-2918
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2023 The Japanese Society of Internal Medicine
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.2169/internalmedicine.0505-22
|
ライセンス | https://creativecommons.org/licenses/by-nc-nd/4.0
|